We previously demonstrated that restoration of TP53 activity in anaplastic thyroid carcinoma inhibits cell growth and induces expression of thyroid differentiation markers. Here, we investigated whether TP53 status may condition the expression of therapeutic genes driven by retroviral LTR or tissue-specific enhancer elements. The TP53-defective ARO anaplastic thyroid carcinoma cells were transfected with TP53
T hyroid carcinomas represent the most common endocrine malignancy, accounting for about 1% of all human cancers. Differentiated thyroid cancers generally respond to conventional therapy and have a relatively good prognosis. At variance, undifferentiated and anaplastic thyroid carcinomas show an aggressive and highly malignant behavior, associated with a poor survival. Since no effective therapy is available for patients with anaplastic thyroid carcinoma, development of innovative therapeutic approaches, including gene therapy, is needed. Different gene therapy approaches have been pursued so far for anaplastic thyroid carcinomas, including TP53 gene transfer, suicide gene therapy, immunotherapy, and viral oncolysis. 1 Evidence from preclinical and clinical studies indicates that interventions combining different therapeutic modalities may result in improved anticancer efficacy. We have recently demonstrated the efficiency of a combined gene therapy approach for this type of cancer, based on retroviral vector-mediated delivery of a cytokine gene (human interleukin-2, hIL-2) together with a suicide gene (thymidine kinase of herpes simplex virus type 1, HSV-TK).
2 An important issue in cancer gene therapy is the need to target therapeutic gene expression in order to prevent side effects to the surrounding healthy tissues. To this aim, we developed a thyroid-specific retroviral vector, in which viral enhancer elements were replaced with human thyroglobulin (TG) enhancer sequences. This vector allowed selective expression of therapeutic genes in differentiated thyroid carcinoma cells, but not in anaplastic thyroid carcinomas and nonthyroid tumor cells, that typically do not express TG. 3 Strategies pursued so far to activate TG-driven therapeutic gene expression in anaplastic thyroid carcinoma cells have been the cotransduction of the thyroid transcription factor-1 (TTF-1) gene 4 or the use of histone deacetylase inhibitors and agents modulating the cAMP pathway 5 to induce TG expression. The approach we followed in this study is based on the induction of a more differentiated phenotype in anaplastic thyroid cells. In this regard, our previous studies demonstrated that recovery of wild-type TP53 activity in ARO anaplastic thyroid carcinoma cells induced expression of thyroid-specific genes, including TG, upon TSH stimulation. 6 In an attempt to develop a targeted therapeutic approach, we investigated in the present study the effects of TP53 restoration on TG enhancer-driven therapeutic genes in anaplastic thyroid carcinoma cells. Since most anaplastic thyroid carcinomas bear TP53 mutations and this molecular defect is responsible for the highly aggressive behavior of this type of cancer, 7 TP53 gene transfer could be per se an effective therapeutic intervention, to be combined with the antitumor activity of suicide and cytokine genes.
Materials and methods

Cell lines and culture conditions
The human anaplastic thyroid carcinoma cell line ARO (UCLA RO-81-A-1, CA) and ARO-derived ARO-Neo, ARO-1F, ARO-4F, ARO-5, and ARO-8 cell clones 6 were cultured in RPMI-1640 medium (Invitrogen S. r.l, San Giuliano Milanese, Italy) supplemented with 10% heatinactivated fetal bovine serum (Invitrogen), 100 U/ml penicillin G and 100 mg/ml streptomycin. ARO cells are characterized by the deletion of one TP53 allele and by the presence, on the other allele, of the Arg273His inactivating mutation. ARO-1F, ARO-4F, ARO-5, and ARO-8 clones were obtained by stable transfection of ARO cells with the pN53cG(Val 135 ) plasmid, encoding for the temperature-sensitive murine TP53
Val135 mutant gene (tsp53), and the selectable marker neomycine phosphotransferase (neo), under the control of the RSV-LTR promoter. The P53
Val135 protein has a mutant conformation at 371C while displays a wild-type-like activity at 321C. 8 These ARO-tsp53 cell clones are characterized by high-level expression and activity of TP53 Val135 , as demonstrated by CDKN1A induction. 6 The plasmid pRSVneo, carrying only the selectable marker neo under the control of the RSV-LTR promoter, was used to transfect control cells (ARO-Neo). Transfected cell clones were maintained under selection with 1 mg/ml G418 (Invitrogen).
The FLYA13 packaging cell line, employed to produce recombinant retroviral vector particles, was maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum and antibiotics, as described. 2 
Construction of recombinant retroviral vectors and retroviral trasduction
Recombinant retroviral vectors were developed from the pMFGIL-2TKSN(TGenh) thyroid-targeted vector and pMFGIL-2TKSN control vector, 3 by substitution of the selectable marker gene neo with the hygromycin phosphotransferase gene. In particular, a 1100 bp DNA fragment encoding the hygromycin phosphotransferase gene was obtained from the pREP4 plasmid (Qiagen S.p.A, Milan, Italy) by BamHI digestion and subcloned into the BamHI site of the pcDNA3.1 plasmid (Invitrogen), downstream a CMV promoter. A DNA fragment containing the CMV promoter and the hygromycin phosphotransferase gene was subsequently excised and ligated into the BamHI site of pMFGIL-2TK(TGenh) and pMFGIL-2TK vectors. The resulting retroviral vectors were named pMFGIL-2TKCH(TGenh) and pMFGIL-2TKCH, respectively. Plasmid vectors were transfected into the FLYA13 packaging cell line by using the Calcium Phosphate Transfection System reagents (Invitrogen), as described. 9 Transfected cells were selected in a medium containing 200 mg/ml hygromycin (ICN, Biomedicals, Asse, Belgium) and single-cell-derived clones isolated and expanded to cell lines. Viral vector titration was performed as described previously. 9 Supernatants from packaging cell clones with higher viral titer were used to transduce ARO anaplastic thyroid carcinoma cell clones.
RNA isolation and quantitative real-time RT-PCR analysis
Total RNA was isolated from cells following a single-step acid guanidium phenol-chlorophorm extraction procedure employing RNAzolt (Biotech Laboratories, Inc., Houston, TX). Random primed cDNAs were generated from total RNA using MuLV reverse transcriptase (Applied Biosystems, Foster City, CA). Real-time quantitative RT-PCR analysis of hIL-2, HSV-TK, TG, TPO, NIS, TSHR, and TTF-1 was performed on the ABI Prism 7700 Sequence Detector (Applied Biosystems), as reported. 3 
ELISA assay of hIL-2
The quantity of hIL-2 secreted into the medium by the different ARO cell clones was measured by using commercial ELISA kits (BioSource, Europe S.A., Nivelles, Belgium) according to the manufacturer's instructions. Briefly, cells were plated at a density of 1 Â 10 5 cells/ well in 24-well cell culture plates and grown at 32 or 371C. After 24 hours, cells were washed twice with PBS and fresh medium was added. Supernatant for hIL-2 ELISA assay was harvested after 24 and 48 hours.
HSV-TK immunofluorescence staining
Approximately 2 Â 10 4 ARO clone cells, grown either at 32 or 371C, were seeded on glass coverslips into 35 mm Petri dishes. After 24 hours, cells were fixed in paraformaldehyde for 10 minutes at room temperature. After washing the slides with PBS and permeabilization, diluted donkey serum was applied for 20 minutes. Thereafter, the slides were incubated overnight (18 hours) at 41C with a polyclonal rabbit antibody anti-HSV-TK at 1:50 dilution (the anti-HSV-TK antibody was kindly provided by Professor A Cavaggioni, Department of Human Anatomy and Physiology, University of Padova, Italy). Incubation with the primary antibody was followed by washing with PBS and by applying a diluted FITCconjugated secondary antibody for 60 minutes. Localization and intensity of fluorescence were observed by confocal laser scanning microscopy. 
Cytotoxicity assay
For cytotoxicity analysis, cells were seeded at density of 5 Â 10 3 cells/well in 96-well microtiter plates. On the next day, the cells were treated with ganciclovir (GCV) (Sigma) concentrations ranging from 0.01 to 100 mM in 100 ml medium, either in the presence or absence of 10 IU/l TSH. Cell survival was quantified by the MTT assay after 6 days of culture at 37 or 321C. 9 Survival ratios were expressed as percentages relative to untreated controls.
Statistical analysis
Results are given as the mean7SD. Comparisons between variables were tested by one-way analysis of variance or Student's t-test, when appropriate. Po.05 was considered statistically significant.
Results
Effect of TP53
Val135 on expression of thyroid-specific genes in anaplastic thyroid carcinoma cells Evaluation of expression of thyroid differentiation marker genes in ARO-Neo and in ARO-tsp53 cell clones was performed in order to confirm that ARO-tsp53 cells, at the permissive temperature for wild-type TP53 activity, exhibited a differentiated thyroid cancer phenotype.
Real-time quantitative RT-PCR analysis showed very low expression of thyroid-specific genes (i.e., TG, TTF-1, TPO, TSHR, and NIS) in ARO-Neo and ARO-tsp53 cell clones, either grown at 37 or at 321C. However, AROtsp53 cell clones grown at 321C showed higher levels of thyroid-differentiation marker genes than cells grown at 371C. These results are in agreement with the more differentiated phenotype shown by ARO-tsp53 when grown at 321C, as reported in our previous study. 6 In order to assess whether TP53 status influenced ARO cell responsiveness to physiological stimuli, such as TSH, ARO and ARO-tsp53 cells were treated with 10 U/l TSH. As shown in Table 1 , at 371C, stimulation with TSH increased, although not significantly, expression of thyroid-specific genes both in ARO-Neo and AROtsp53 cells. At 321C, TSH treatment resulted in a significant enhancement of expression of these thyroid differentiation genes in ARO-tsp53 cells, but not ARONeo cells, thus showing that cells with wild-type TP53 activity responded to TSH stimulation (Table 1) .
Taken together, these results demonstrate that AROtsp53 cells grown at 371C behave like parental ARO-Neo anaplastic thyroid carcinoma cells, whereas the same cells, grown at 321C, displayed a differentiated thyroid carcinoma phenotype. This model was employed to evaluate activity of wild-type LTR and transcriptionally targeted LTR in anaplastic and differentiated thyroid carcinoma cells, minimizing variables related to the use of different cell types. Table 2 ). In particular, in ARO-Neo cells, grown either at 37 or 321C, expression of therapeutic genes driven by TG enhancer was 10-35-fold lower than that obtained after infection with the control vector having wild-type LTR. TSH treatment, which was employed to activate expression of genes driven by the TG enhancer in the chimaeric LTR, did not significantly modify transgene expression in ARO-Neo cells. In AROtsp53 cells grown at 371C, although with wide variability due to experimental methods and the different cell clones employed, expression of therapeutic genes driven by wildtype LTR was about 5-8-fold lower than in ARO-Neo control cells, whereas expression of transgenes under the control of TG enhancer was unchanged or slightly increased. In ARO-tsp53 cells grown at 321C and in the presence of TSH, the inhibitory effect of TP53 Val135 on retroviral LTR and the stimulating effect on human TG enhancer was more pronounced, so that therapeutic gene expression under the control of the transcriptionally targeted LTR was similar to that obtained with the wild-type LTR retroviral vector ( Table 2) .
The results on therapeutic gene expression obtained by real-time quantitative RT-PCR analysis were confirmed by evalution of hIL-2 protein secretion by transduced cells into the culture medium by ELISA assay (Table 3) . Production of IL-2 by the vector with wild-type LTR was higher in ARO cells with inactive TP53 than in those in which TP53 activity was restored. At variance, IL-2 secretion driven by the vector with transcriptionally targeted LTR was very low in ARO-Neo cells, but significantly increased in ARO-tsp53 cells grown at 321C.
Analysis of HSV-TK expression at the protein levels was performed by indirect immunofluorescence using polyclonal anti-HSV-TK antibody. Although the fluorescence signal of HSV-TK-positive cells was generally faint, intensity of HSV-TK expression by immunofluorescence seemed to parallel the level of IL-2 production by the same cells. Representative results of HSV-TK expression by immunofluorescence are shown in Figure 1 .
GCV sensitivity of infected cells
Sensitivity to GCV of parental and infected ARO cell clones was assessed by determining the IC50 by the MTT assay (Fig 2) . In ARO-Neo cells grown at 371C, GCV was significantly more effective when cells where transduced with the MFGIL-2TKCH vector than with the thyroid targeted MFGIL-2TKCH (TGenh) vector, with IC 50 of 0.01-0.1 and 100-1.000 mM, respectively. At 321C, GCV cytotoxicity decreased, probably because of a reduction of cell proliferation rate. In ARO-tsp53 clones transduced 
Discussion
This study demonstrates that mutations in the TP53 gene, which are generally found in undifferentiated and anaplastic thyroid carcinomas, not only play a critical role in loss of differentiated phenotype, but may also modulate expression of transgenes driven by retroviral vector LTR or cellular tissue-specific transcription control elements. These findings have relevance in the design of retroviral vector-based gene therapy strategies for cancer.
Our study springs from our previous observations and from data from the literature, showing that TP53 mutations induce TSH-independent growth and inhibit expression of thyroid-specific genes, 6, 10, 11 and that these abnormalities can be reverted by re-expression of wildtype TP53. 6, [12] [13] [14] [15] [16] [17] [18] We attempted here a gene therapy approach in which TP53-mediated tumor cell differentiation was combined with the delivery of suicide and cytokine genes under the control of TG enhancer.
To evaluate the efficacy of this strategy, we employed a temperature-sensitive mutant form of P53. In particular, in order to minimize the number of experimental variables, we transfected ARO human anaplastic thyroid carcinoma cells, which bear the hot-spot TP53 His273 mutation, with temperature-sensitive TP53
Val135 , which exhibits a nuclear-localized wild-type P53 conformation at 321C, but a cytoplasmic-localized mutant conformation at 371C. 19 Transduction of these cells with retroviral vectors carrying either wild-type LTR or transcriptionally targeted reshuffled LTR, 3 showed that TP53 Val135 transfer inhibited expression of LTR-driven transgenes but enhanced expression of transgenes under the control of human TG enhancer.
Repression of transcription from viral promoters, including retroviral LTR, by wild-type TP53 has been already demonstrated in the literature, 20,21 whereas mutant TP53 has been shown to directly activate several viral genes. 20, [22] [23] [24] For example, P53 His273 has been shown to interact directly with cellular transcription factors, such as Sp1, and to transactivate HIV-LTR by binding target DNA sequences. 24 Moreover, expression of temperature sensitive P53
Val135 was able to block the transactivation activity of the endogenous mutant P53
His273 at both 37 TP53 and retroviral vectors for thyroid cancer L Barzon et al Figure 2 In vitro cytotoxicity of GCV in ARO-Neo (a) and ARO-tsp53 (b, c) cell clones either noninfected or transduced with MFGIL-2TKCH(TGenh) or MFGIL-2TKCH vectors. Cells were grown at 37 or 321C and incubated with various concentrations of GCV for 6 days, followed by cell survival quantification by MTT assay. IC 50 was calculated as the concentration of drug which inhibits cell growth by 50%. Data are representative of at least three separate experiments performed in sestuplicate; each point represents the mean7SD and is expressed as percentage relative to drug-free cells.
TP53 and retroviral vectors for thyroid cancer L Barzon et al and 321C. 24 It is conceivable that, at 371C, P53
Val135 prevented nuclear localization of P53, whereas the inhibition shown at 321C could be due to a direct effect of the wild-type conformation achieved by the protein.
Wild-type TP53 generally inhibits transcription from cellular promoters, whereas mutant TP53 can activate transcription of cellular genes involved in cell proliferation and tumorigenesis, even though effects may vary with type of mutation and cellular environment. 20, 21, 25 As shown by our results in the TP53-defective ARO anaplastic thyroid carcinoma cell line, expression of TP53 Val135 inhibited cell proliferation and restored expression of thyroid differentiation marker genes, including TG, and TSH responsiveness. Since the chimaeric LTR containing a human TG enhancer sequence was also activated by TP53
Val135 transfer, it is conceivable that this sequence, which contains several TTF-1-binding sites and binding sites for CREB and a CREB-associated factor, 26 is involved in TP53-mediated transactivation.
The results of this study could be of interest for the design of retroviral vector-based gene therapy protocols for patients with thyroid cancer. As demonstrated by our pilot experience in two patients with anaplastic thyroid carcinoma, thyroid cancer is a suitable target for gene therapy protocols based on direct intratumor delivery of retroviral vectors or retroviral vector producing cells. 1 Reasons are twofold: the anatomical location of the tumor, which allows easy access, and the high proliferation rate of neoplastic cells, which can be selectively transduced by this type of vector.
In conclusion, our results demonstrate that P53 status in the tumor cell can influence expression of therapeutic genes in the context of gene therapy. Wild-type and mutant P53 may elicit either a stimulating or an inhibiting effect on transgene expression, according to the cellular or viral promoter that has been employed. As for thyroid cancer, wild-type P53 stimulates expression of thyroid-specific genes, including TG, but represses transcription from retroviral LTR. At variance, mutant P53 can transactivate retroviral LTR and downregulate expression of thyroid-specific genes. Thus, when using retroviral vector-based gene therapy, wild-type LTR vectors should be used to target thyroid carcinomas carrying mutations in the TP53 gene, whereas thyroid-specific cellular promoters should be employed for a transcriptionally targeted approach in tumors carrying wild-type TP53. Our results also show that multimodality gene therapy approaches should be carefully evaluated, since they may not always have synergistic or additive effects, but may also act antagonistically.
